Responses
Therapeutics/Prevention
Randomised controlled trial
In individuals at intermediate risk for cardiovascular disease, treatment with rosuvastatin but not candesartan plus hydrochlorothiazide lowers cardiovascular disease event rates
Compose a Response to This Article
Other responses
No responses have been published for this article.